SCHEMBL23055151

SCHEMBL23055151

CC[C@@H](NC(=O)[C@H](CO)NC(=O)OCc1ccccc1)C(=O)OC

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.58
KYNU Q16719 1/20 0.56
ALDH1A1 P00352 2/20 0.54
ALOX15 P16050 1/20 0.54
CAPN1 P07384 1/20 0.53
THRB P10828 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CTSS P25774 4/20 0.52
CTSL P07711 3/20 0.52
CTSB P07858 2/20 0.52
TACR1 P25103 2/20 0.50
GLS O94925 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.49
SIRT1 Q96EB6 1/20 0.49
SIRT3 Q9NTG7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31248222 1.00 CTSK (0.58) CTSKKYNUALDH1A1ALOX15CAPN1
SCHEMBL23058683 1.00 CTSK (0.58) CTSKKYNUALDH1A1ALOX15CAPN1
SCHEMBL6826924 0.94 KYNU (0.59) CTSKKYNUALDH1A1ALOX15CAPN1
SCHEMBL6831659 0.94 KYNU (0.59) CTSKKYNUALDH1A1ALOX15CAPN1
SCHEMBL1760460 0.94 KYNU (0.59) CTSKKYNUALDH1A1ALOX15CAPN1
SCHEMBL23039999 0.91 CTSK (0.59) CTSKCAPN1CTSSCTSLCTSB
SCHEMBL23040001 0.91 CTSK (0.59) CTSKCAPN1CTSSCTSLCTSB
SCHEMBL12406843 0.91 KYNU (0.64) CTSKKYNUALDH1A1ALOX15CTSS
SCHEMBL8170978 0.91 KYNU (0.64) CTSKKYNUALDH1A1ALOX15CTSS
SCHEMBL12189890 0.91 KYNU (0.64) CTSKKYNUALDH1A1ALOX15CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4021901-B1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2025-09-24 EP disclosed
US-20240400563-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-05 US disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
CN-114302884-B Substituted pyridopyrimidinone compounds useful as T cell activators 百时美施贵宝公司 2024-06-04 CN disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
EP-4021901-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2022-07-06 EP disclosed
CN-114302884-A Substituted pyridopyrimidinone based compounds useful as T cell activators 百时美施贵宝公司 2022-04-08 CN disclosed
WO-2021041588-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-04 WO disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG CTSK 795/4885KYNU 2772/4885ALDH1A1 4233/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CTSK 795/4885KYNU 2772/4885ALDH1A1 4233/4885
US-20240400563-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CTSK 795/4885KYNU 2772/4885ALDH1A1 4233/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK CTSK 388/4885KYNU 2200/4885ALDH1A1 1296/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK CTSK 388/4885KYNU 2200/4885ALDH1A1 1296/4885
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CTSK 779/4885KYNU 2995/4885ALDH1A1 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.